stockrowOrganon & Co.
OGNHealthcare Drug Manufacturers General
Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024.
- Revenue
- −1.75%
- EPS
- +1.64%
- Free cash flow
- +118.8%
- Total debt
- −3.10%
Quarter to September 2026, against a year earlier
Follow OGN
Alert me
Organon & Co. (OGN) Return on equity
Organon & Co.'s return on equity over the twelve months to 30 September 2026 was 20.3%, down 10.3 percentage points from fiscal 2025 (30.6%). Over the past ten years it has ranged from −212.7% (fiscal 2023) to 429.9% (fiscal 2024); the current reading is higher than 44% of that period. That is above the Drug Manufacturers General industry median of 5.80% and above the Healthcare sector median of −26.0%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 30.6% | (399.29) |
| FY2024 | 429.9% | 642.53 |
| FY2023 | −212.7% | (136.26) |
| FY2022 | −76.4% | (144.34) |
| FY2021 | 67.9% | 33.42 |
| FY2020 | 34.5% | (13.59) |
| FY2019 | 48.1% | 15.91 |
| FY2018 | 32.2% | 32.18 |
| FY2017 | 0.00% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| NVO Novo Nordisk A/S compare | 58.8% |
| BMY Bristol Myers Squibb Company compare | 44.0% |
| GSK GSK PLC Sponsored ADR compare | 25.5% |
| OGN Organon & Co. | 20.3% |
| GRFS Grifols, S.A. compare | 5.80% |
| PFE Pfizer Inc. compare | 4.42% |
| BIIB Biogen Inc. compare | 1.87% |
| SNY Sanofi compare | 0.00% |
| AMRN Amarin Corporation PLC compare | −4.24% |
| Drug Manufacturers General industry median | 5.80% |
| Healthcare sector median | −26.0% |
| Market median | 1.01% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on OGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement